Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how optimizing dosing intervals and carefully considering combination strategies for bispecific antibodies in relapsed/refractory multiple myeloma could enhance treatment efficacy while managing toxicities and improving patient quality of life.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
2 experts in this video
2 experts in this video
2 experts in this video
Related Content